Sozinibercept (OPT-302)
Lymphangioleiomyomatosis (LAM)
Key Facts
About Opthea
Opthea's mission is to develop first-in-class VEGF-C/D inhibition therapies for diseases driven by abnormal vascular and lymphatic growth. The company's key achievement is the development of sozinibercept (OPT-302), a soluble 'trap' molecule that has completed Phase 2b/3 trials in wet age-related macular degeneration (AMD). Its current strategy is a decisive pivot to apply this validated platform to Lymphangioleiomyomatosis (LAM), targeting a high-unmet-need rare disease with a clear biological rationale and potential for accelerated development and regulatory pathways.
View full company profileAbout Opthea
Opthea's mission is to develop first-in-class VEGF-C/D inhibition therapies for diseases driven by abnormal vascular and lymphatic growth. The company's key achievement is the development of sozinibercept (OPT-302), a soluble 'trap' molecule that has completed Phase 2b/3 trials in wet age-related macular degeneration (AMD). Its current strategy is a decisive pivot to apply this validated platform to Lymphangioleiomyomatosis (LAM), targeting a high-unmet-need rare disease with a clear biological rationale and potential for accelerated development and regulatory pathways.
View full company profileAbout Opthea
Opthea's mission is to develop first-in-class VEGF-C/D inhibition therapies for diseases driven by abnormal vascular and lymphatic growth. The company's key achievement is the development of sozinibercept (OPT-302), a soluble 'trap' molecule that has completed Phase 2b/3 trials in wet age-related macular degeneration (AMD). Its current strategy is a decisive pivot to apply this validated platform to Lymphangioleiomyomatosis (LAM), targeting a high-unmet-need rare disease with a clear biological rationale and potential for accelerated development and regulatory pathways.
View full company profile